EQT Growth leads USD 85 million investment round into global corporate wellness platform Gympass

2023-08-23
STOCKHOLM, Aug. 23, 2023 /PRNewswire/ --
New York-based Gympass allows its base of over two million employee subscribers to access a global network of over 50,000 gyms, studios, classes, personal trainers, and wellness apps although though one employee benefit
The USD 85 million investment round will help Gympass accelerate growth across its 11 global markets, as employers prioritize decreasing healthcare costs and improving employee wellbeing
EQT Growth, in partnership with the company's management team and existing investors, will support the company in the next leg of its growth journey, leveraging its in-house digital business development experts to continue to deepen Gympass' network and global leadership
EQT is pleased to announce that the EQT Growth fund ("EQT Growth") has invested in Gympass (or the "Company"), as part of its $85m Series F round. The round also saw participation from Neuberger Berman client funds and existing investors. Carolina Brochado, Deputy Head of the EQT Growth Advisory team, will join the Gympass Board.
Founded in 2012 and based in New York, Gympass is a leading corporate wellness platform, providings access to a network of over 50,000 gyms, studios, classes, personal trainers, and wellness apps through a single employee benefit. With over two million global employee subscribers, Gympass supports companies around the world to retain employees, drive productivity, and reduce healthcare costs.
Gympass has seen 80% year-on-year growth in its customer base over the last year, on the back of strong adoption tailwinds for its platform. For example, four out of five employees globally believe wellbeing is equally important to salary, according to the Gympass Work-Life Wellness Report 2022. As a result of its powerful platform, Gympass has more than doubled the average number of employees engaged with wellness at its corporate customers and has thereby grown the market, all while driving improved employee happiness and health.
EQT Growth will support Gympass in its next phase of growth, drawing on EQT's presence in over 20 countries across the world. It will leverage its in-house digital business development experts, as well as its extensive network of industrial advisors to help Gympass continue to deepen its reach and global leadership. EQT Growth will also support further investment in the Company's product capabilities.
Carolina Brochado, Deputy Head of the EQT Growth Advisory team, said: "For years we have watched the Gympass team exceed expectations again and again. Their powerful recurring model, which now reaches 11 markets globally, sees clear and strong network effects the more it scales. It enables Gympass to deliver a diverse and growing network of partners, thereby reaching employees who might not have previously had access to wellness activities and as a result further expanding the market. We are really excited to be helping this stellar management team continue to build a healthier, happier, and more productive corporate world."
Cesar Carvalho, Co-Founder and CEO of Gympass, said: "We live in a time where companies globally are making investments to drive efficient growth and reduce spending. Organizations are shifting from reactive and traditional healthcare benefits that increase costs, to more holistic and preventative wellness benefits that reduce costs and improve employee wellbeing and productivity. With the support of EQT Growth and our other investors, we look forward to further accelerating our growth and reach so that we can improve the wellbeing of even more employees around the world."
Contact
Finn McLaughlan, [email protected], +44 771 534 1608
EQT Press Office, [email protected], +46 8 506 55 334
The following files are available for download:
SOURCE EQT
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。